International Journal of ADVANCED RESEARCH & INNOVATIONS

Volume 13, Issue-12
December, 2023, P06
ISSN: 2319-9253

AI-DRIVEN PRECISION CLINICAL TRIALS: FOUNDATION MODELS FOR ADAPTIVE ONCOLOGY RESEARCH AND PERSONALIZED THERAPEUTICS

[#1]**Dr. Nikhil Varma,** Professor, Department of Medical Oncology,
Malla Reddy Medical College for Women, Hyderabad, India
Nikhilvarma82@gmail.com

[#2]**Dr. Asha Krishnan,** Associate Professor, Department of Pharmacology,
Malla Reddy Medical College for Women, Hyderabad, India
Ashakrishnan56@gmail.com

Abstract: Artificial intelligence (AI) is fundamentally transforming oncology clinical research through the emergence of foundation models capable of enabling adaptive, data-driven, and patient-centered clinical trials. Conventional oncology trials frequently face substantial challenges including prolonged patient recruitment, heterogeneous populations, limited biomarker stratification, high operational costs, delayed endpoint evaluation, and restricted generalizability. Recent advances in foundation AI models, multimodal transformer architectures, graph neural networks, self-supervised learning, reinforcement learning, and generative artificial intelligence have enabled comprehensive integration of radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, epigenomics, spatial biology, laboratory biomarkers, circulating tumor DNA, wearable physiological monitoring, electronic health records, biomedical literature, and longitudinal clinical outcomes into unified computational frameworks. These intelligent systems support patient identification, biomarker discovery, adaptive trial design, prognostic prediction, therapeutic optimization, immunotherapy selection, digital twin simulation, real-time safety monitoring, and evidence-based clinical decision support. Emerging technologies including multimodal large language models, federated learning, retrieval-augmented generation, explainable artificial intelligence, agentic AI, cloud-native clinical research platforms, and digital biomarkers further strengthen precision clinical trials by enabling collaborative, privacy-preserving, transparent, and continuously adaptive biomedical intelligence. Despite remarkable technological advances, important scientific, technical, ethical, regulatory, and implementation challenges remain regarding multimodal data harmonization, computational scalability, interoperability, cybersecurity, clinical validation, regulatory acceptance, and equitable implementation. This review provides a comprehensive overview of AI-driven precision clinical trials, emphasizing foundation models for adaptive oncology research and personalized therapeutics.[1]

Keywords: *Precision clinical trials, Foundation models, Artificial intelligence, Adaptive oncology, Personalized therapeutics, Computational oncology, Clinical research, Digital biomarkers, Clinical decision support, Precision medicine.*

1. Introduction

Clinical trials represent the foundation of evidence generation in oncology by establishing the safety and efficacy of novel diagnostic technologies, therapeutic interventions, biomarkers, and precision medicine strategies. However, conventional oncology trials frequently encounter challenges including slow patient recruitment, heterogeneous study populations, limited molecular stratification, operational complexity, and delayed translation of research findings into routine clinical practice.[2]

Modern oncology generates enormous quantities of biomedical information through radiological

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv13i1206

Volume 13, Issue-12
December, 2023, P06
ISSN: 2319-9253

imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, epigenomics, spatial biology, laboratory investigations, circulating tumor DNA, wearable physiological monitoring, physician documentation, electronic health records, biomedical literature, and patient-reported outcomes. Although each modality contributes valuable biological insight, isolated interpretation frequently limits the ability to optimize clinical trial design, patient selection, therapeutic evaluation, and biomarker validation.[3]

Artificial intelligence has emerged as a transformative computational technology capable of integrating these heterogeneous biomedical datasets into unified patient-centered representations. Foundation AI models extend these capabilities by enabling adaptive clinical trial design, continuous learning, intelligent patient stratification, and personalized therapeutic evaluation throughout oncology research.

The convergence of artificial intelligence and adaptive clinical research therefore establishes a transformative paradigm for next-generation precision oncology.[4]

2. Evolution of Clinical Trials in Precision Oncology

Oncology clinical research has evolved from conventional population-based randomized trials toward increasingly individualized precision medicine studies. Early clinical trials primarily stratified patients according to anatomical tumor classification and histopathological diagnosis, while later genomic technologies introduced molecularly targeted therapeutic strategies based on specific genetic alterations.[5]

Deep learning substantially expanded computational capabilities by enabling automated analysis of radiological imaging, digital pathology, genomic sequencing, and electronic health records. Transformer architectures subsequently revolutionized biomedical artificial intelligence by enabling generalized contextual learning across heterogeneous biomedical modalities.

Foundation AI models now acquire transferable biomedical knowledge through large-scale self-supervised pretraining, enabling adaptive patient recruitment, biomarker discovery, therapeutic optimization, digital trial monitoring, and intelligent evidence generation throughout precision oncology.[6]

3. Principles of Foundation AI Models in Clinical Trials

Foundation AI models differ fundamentally from conventional artificial intelligence because they acquire generalized biomedical representations from massive multimodal datasets before specialization for individual oncology research applications. Rather than learning isolated predictive tasks, these models develop transferable computational knowledge applicable across patient recruitment, biomarker discovery, diagnosis, prognosis, therapeutic optimization, disease monitoring, adaptive trial design, and clinical decision support.[7]

Self-supervised learning enables discovery of latent biological relationships without requiring extensive manual annotation, while multimodal transformer architectures align radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, laboratory biomarkers, wearable physiological monitoring, physician documentation, patient-reported outcomes, biomedical literature, and longitudinal clinical trajectories within unified computational embedding spaces.

Graph neural networks further characterize interactions among genes, proteins, signaling pathways, immune populations, imaging phenotypes, tissue architecture, therapeutic targets, physiological variables, environmental exposures, and clinical outcomes, thereby enabling systems-level computational reasoning supporting adaptive oncology research.[8]

4. Computational Architecture

Modern AI-driven clinical trial platforms consist of interconnected computational layers responsible for biomedical data acquisition, preprocessing, representation learning, multimodal fusion, adaptive learning, predictive analytics, digital twin simulation, trial optimization, and intelligent clinical decision support.[9]

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv13i1206

Volume 13, Issue-12
December, 2023, P06
ISSN: 2319-9253

The acquisition layer continuously integrates radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, epigenomics, spatial biology, laboratory investigations, circulating tumor DNA, wearable physiological monitoring, medication history, physician documentation, patient-reported outcomes, biomedical literature, and electronic health records. Advanced preprocessing pipelines normalize imaging studies, harmonize molecular datasets, encode clinical narratives using natural language processing, synchronize temporal patient information, and continuously incorporate evolving clinical evidence.

Foundation AI models subsequently generate generalized multimodal embeddings representing molecular biology, tissue architecture, imaging phenotypes, physiological function, environmental exposures, and longitudinal clinical trajectories. These unified computational representations support adaptive clinical research and precision oncology.[10]

5. Artificial Intelligence for Patient Recruitment

Patient recruitment remains one of the greatest challenges in oncology clinical trials because eligibility criteria often involve complex combinations of molecular alterations, histopathological findings, imaging characteristics, laboratory biomarkers, treatment history, and clinical outcomes. Foundation AI models substantially improve recruitment by automatically identifying eligible patients through comprehensive analysis of electronic health records, molecular diagnostics, radiological imaging, pathology reports, laboratory investigations, and physician documentation.[11]

Natural language processing extracts clinically relevant information from unstructured medical records, while multimodal AI integrates molecular biomarkers, disease stage, therapeutic history, and physiological information into comprehensive eligibility assessments. These computational approaches substantially reduce recruitment time, improve trial efficiency, minimize screening failures, and enhance patient access to innovative therapies.

AI-assisted recruitment therefore accelerates adaptive clinical research while strengthening precision oncology.[12]

6. Biomarker-Driven Trial Design

Comprehensive biomarker characterization represents one of the greatest strengths of AI-driven precision clinical trials. Artificial intelligence integrates genomics, transcriptomics, proteomics, metabolomics, epigenomics, immunomics, microbiomics, spatial biology, circulating tumor DNA, radiological imaging, and digital pathology into generalized molecular representations capable of identifying clinically meaningful therapeutic biomarkers.[13]

Transformer architectures identify latent biological relationships among genes, proteins, signaling pathways, metabolites, immune responses, and therapeutic targets, while graph neural networks model complex biological interaction networks supporting systems-level computational reasoning.

These integrated biomarker representations substantially improve patient stratification, therapeutic selection, adaptive randomization, response prediction, and personalized clinical trial design.[14]

7. Adaptive Trial Design Through Artificial Intelligence

Adaptive clinical trials dynamically modify enrollment strategies, treatment allocation, biomarker stratification, dose optimization, endpoint evaluation, and statistical analyses according to accumulating clinical evidence. Foundation AI models continuously analyze emerging trial data, molecular biomarkers, radiological imaging, laboratory investigations, safety outcomes, and therapeutic responses to optimize ongoing trial conduct while preserving scientific validity.[15]

Reinforcement learning algorithms evaluate alternative trial strategies, Bayesian adaptive frameworks support real-time evidence updating, and predictive models estimate treatment efficacy across molecularly defined patient populations. These adaptive computational approaches substantially improve trial efficiency, reduce unnecessary patient exposure to ineffective

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv13i1206

Volume 13, Issue-12
December, 2023, P06
ISSN: 2319-9253

therapies, accelerate regulatory evaluation, and enhance precision medicine.
Adaptive trial design therefore represents a major advancement in oncology research enabled by artificial intelligence.[16]

8. Digital Biomarkers and Remote Trial Monitoring

Digital biomarkers derived from wearable biosensors, mobile health technologies, remote physiological monitoring, and patient-reported outcomes have transformed clinical trial monitoring by enabling continuous assessment of treatment response, toxicity, functional status, medication adherence, and quality of life outside conventional healthcare settings.[17]
Foundation AI models integrate wearable physiological measurements with laboratory biomarkers, radiological imaging, molecular biology, digital pathology, and longitudinal clinical information using multimodal transformers and graph neural networks. These integrated computational representations substantially improve early toxicity detection, adverse event monitoring, treatment adherence assessment, endpoint evaluation, and decentralized clinical trial management.
Continuous digital monitoring therefore strengthens adaptive precision clinical trials while improving patient engagement and real-world evidence generation.[18]

9. Personalized Therapeutic Evaluation

One of the most clinically significant applications of AI-driven precision clinical trials is individualized therapeutic evaluation through comprehensive integration of molecular biology, imaging phenotypes, histopathological characteristics, laboratory biomarkers, wearable physiological monitoring, medication history, physician documentation, environmental exposures, and longitudinal clinical trajectories. Foundation AI models continuously predict therapeutic responsiveness, treatment-related toxicity, disease progression, recurrence risk, and survival outcomes while adapting trial recommendations according to evolving patient biology, treatment response, and accumulating clinical evidence. These adaptive computational systems establish a comprehensive framework for personalized oncology research capable of accelerating therapeutic discovery and precision medicine throughout the cancer care continuum.[19][20]

10. Digital Twins and Virtual Clinical Trial Simulation

Digital twin technology represents one of the most transformative applications of AI-driven precision clinical trials by creating continuously evolving virtual representations of individual cancer patients synchronized with their biological counterparts. Foundation AI models integrate serial radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, laboratory biomarkers, circulating tumor DNA, wearable physiological monitoring, medication history, patient-reported outcomes, and longitudinal clinical information into adaptive computational patient models capable of simulating disease progression, therapeutic response, treatment-related toxicity, recurrence, metastatic dissemination, and survival.[21]
Unlike conventional clinical trial methodologies, digital twins continuously update their computational representations as new biomedical information becomes available. Integration of multimodal molecular biology with predictive simulation enables virtual patients to evaluate alternative therapeutic strategies, optimize treatment sequencing, anticipate mechanisms of therapeutic resistance, and personalize supportive care according to evolving patient biology. Digital twin technology also enables simulation of adaptive trial scenarios, estimation of treatment effects, optimization of inclusion criteria, and evaluation of alternative study designs before patient enrollment.
By combining multimodal biomedical intelligence with predictive simulation, digital twins transform oncology research from retrospective evaluation toward proactive, adaptive, and continuously learning precision clinical trials.

11. Intelligent Clinical Decision Support

Foundation AI models provide the computational infrastructure for next-generation clinical decision-support systems capable of integrating

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv13i1206

Volume 13, Issue-12
December, 2023, P06
ISSN: 2319-9253

heterogeneous biomedical information into comprehensive patient-centered recommendations throughout oncology research. Rather than interpreting radiological imaging, digital pathology, molecular diagnostics, laboratory investigations, wearable physiological monitoring, medication history, physician documentation, patient-reported outcomes, and evidence-based clinical guidelines independently, these models synthesize diverse biomedical information into unified computational representations supporting multidisciplinary oncology practice and clinical trial decision-making.[22]

Interactive clinical dashboards generate individualized diagnostic summaries, biomarker analyses, molecular interpretations, digital twin simulations, therapeutic recommendations, toxicity estimates, recurrence probabilities, disease progression forecasts, survival predictions, trial eligibility assessments, and adaptive endpoint analyses while facilitating collaboration among oncologists, radiologists, pathologists, surgeons, radiation oncologists, molecular biologists, pharmacists, clinical trial investigators, nurses, genetic counselors, statisticians, and computational scientists.

These intelligent systems improve workflow efficiency, strengthen multidisciplinary communication, reduce information fragmentation, and promote evidence-based precision oncology research.

12. Continuous Learning and Adaptive Clinical Research

A defining characteristic of AI-driven precision clinical trials is the ability to continuously evolve as new biomedical information becomes available. Artificial intelligence incorporates serial imaging examinations, computational pathology, circulating tumor DNA, laboratory biomarkers, wearable physiological monitoring, medication adherence, patient-reported outcomes, biomedical literature, and real-world clinical evidence into adaptive computational frameworks capable of continuously refining predictive accuracy throughout ongoing clinical investigations.[23]

Continual learning algorithms enable incremental refinement of computational knowledge without catastrophic forgetting of previously acquired information, while reinforcement learning optimizes trial design, therapeutic recommendations, and endpoint evaluation through iterative analysis of treatment outcomes. Consequently, adaptive oncology research platforms remain synchronized with evolving tumor biology, emerging scientific discoveries, changing therapeutic guidelines, and diverse patient populations.

This adaptive computational paradigm transforms oncology research into a continuously learning scientific ecosystem capable of accelerating therapeutic innovation.

13. Federated Precision Clinical Trial Networks

Development of highly generalizable foundation AI models for oncology research requires access to diverse biomedical datasets representing multiple healthcare systems, imaging platforms, pathology laboratories, molecular technologies, treatment protocols, and patient populations. Federated learning enables collaborative development of foundation AI models while preserving patient privacy and institutional governance through decentralized computational training.[24]

Participating healthcare institutions independently train local models using radiological imaging, digital pathology, genomics, transcriptomics, laboratory investigations, wearable monitoring, liquid biopsy, electronic health records, and longitudinal clinical records while securely exchanging encrypted model parameters rather than identifiable patient information. This collaborative learning strategy substantially improves algorithm robustness, fairness, external validity, transparency, and generalizability across diverse healthcare environments.

Federated clinical research ecosystems therefore establish international oncology trial networks capable of accelerating scientific discovery, improving equitable access to innovative therapeutics, and supporting global precision medicine while maintaining responsible biomedical data stewardship.

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv13i1206

Volume 13, Issue-12
December, 2023, P06
ISSN: 2319-9253

14. Explainability, Validation, and Ethical Governance

Successful implementation of AI-driven precision clinical trials requires transparent, interpretable, reproducible, and rigorously validated computational systems capable of supporting investigator confidence, patient trust, and regulatory approval. Explainable artificial intelligence (XAI) enables clinicians and researchers to understand computational reasoning through attention visualization, saliency maps, SHAP (Shapley Additive Explanations), feature attribution analysis, uncertainty estimation, multimodal attention mapping, and counterfactual explanations identifying the imaging, molecular, pathological, physiological, and clinical variables responsible for predictive outputs.[25]

Clinical deployment additionally requires standardized multimodal datasets, interoperable computational infrastructure, prospective multicenter validation, external benchmarking, cybersecurity safeguards, continuous monitoring for algorithmic bias, transparent reporting standards, and compliance with evolving international regulatory frameworks governing AI-enabled healthcare technologies and adaptive clinical research.

Responsible implementation further depends upon patient privacy, informed consent, transparency, accountability, equitable access, responsible data governance, continuous post-deployment surveillance, and multidisciplinary oversight to ensure trustworthy integration of artificial intelligence into oncology clinical trials.

15. Future Perspectives

Future AI-driven precision clinical trial ecosystems will increasingly integrate multimodal foundation models, multimodal large language models, agentic artificial intelligence, graph neural networks, reinforcement learning, federated learning, digital twins, spatial multi-omics, single-cell sequencing, liquid biopsy, quantum computing, Internet of Medical Things (IoMT), robotics, cloud-native clinical research infrastructure, and autonomous trial management systems into unified precision oncology platforms.[26]

These next-generation computational ecosystems will continuously integrate molecular biology, radiological imaging, digital pathology, laboratory medicine, wearable physiological monitoring, environmental exposures, electronic health records, biomedical literature, pharmacological databases, and real-world clinical outcomes while autonomously coordinating patient recruitment, adaptive randomization, biomarker validation, endpoint evaluation, therapeutic optimization, and continuous evidence synthesis.

Such intelligent clinical research ecosystems are expected to transform oncology from conventional trial methodologies toward predictive, adaptive, continuously learning, biomarker-driven, and precision-guided therapeutic development.

16. Discussion

AI-driven precision clinical trials represent one of the most significant paradigm shifts in oncology research by integrating foundation AI models, multimodal biomedical intelligence, digital biomarkers, digital twins, molecular biology, radiological imaging, digital pathology, laboratory biomarkers, wearable technologies, and longitudinal clinical intelligence into unified computational ecosystems capable of supporting adaptive therapeutic development. Unlike conventional clinical trial methodologies based upon static protocols, intelligent trial ecosystems continuously analyze evolving biomedical information, optimize recruitment strategies, refine biomarker selection, personalize therapeutic evaluation, and accelerate scientific discovery through adaptive computational reasoning.[27]

Applications spanning computational pathology, radiogenomics, biomarker discovery, digital twins, precision immunotherapy, adaptive therapeutics, decentralized clinical trials, continuous learning, federated collaboration, digital health, survivorship management, and intelligent clinical decision support demonstrate the extraordinary potential of foundation AI models to redefine future oncology research. Nevertheless, successful implementation requires continued advances in multimodal data harmonization, explainable artificial intelligence, interoperability, computational infrastructure, cybersecurity, regulatory science, ethical

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv13i1206

governance, and sustained multidisciplinary collaboration.

As biomedical knowledge and healthcare data continue to expand exponentially, AI-driven precision clinical trials are expected to become one of the foundational scientific infrastructures supporting precision oncology worldwide.

17. Conclusion

AI-driven precision clinical trials are transforming oncology research by integrating foundation AI models, radiological imaging, digital pathology, multi-omics, laboratory biomarkers, wearable technologies, electronic health records, digital biomarkers, digital twins, and longitudinal clinical intelligence into unified computational ecosystems capable of supporting intelligent patient recruitment, biomarker discovery, prognostic prediction, adaptive therapeutic evaluation, continuous disease monitoring, and personalized cancer treatment throughout the research and clinical care continuum.[28]

Advances in transformer architectures, multimodal learning, graph neural networks, self-supervised learning, federated learning, reinforcement learning, digital twins, multimodal large language models, agentic AI, and generative artificial intelligence are expected to further strengthen adaptive oncology research ecosystems, enabling increasingly accurate molecular characterization, predictive clinical intelligence, adaptive therapeutics, accelerated therapeutic discovery, and continuously personalized precision medicine.[29]

Although important scientific, technical, ethical, regulatory, and implementation challenges remain, sustained collaboration among oncologists, radiologists, pathologists, molecular biologists, biomedical engineers, computer scientists, healthcare organizations, policymakers, industry partners, regulatory agencies, and clinical trial organizations will accelerate the responsible implementation of AI-driven precision clinical trials. These innovations have the potential to improve patient outcomes, enhance research efficiency, reduce disparities in cancer care, accelerate translational medicine, and establish a new era of intelligent, adaptive, and continuously learning precision oncology worldwide.[30]

References

1. Meric-Bernstam, F. et al. (2023) 'Enhancing Precision Oncology Through Multimodal Data Integration', Nature Reviews Clinical Oncology, 20(4), pp. 267-283.
2. Xu H, Usuyama N, Bagga J, et al. A whole-slide foundation model for digital pathology from real-world data. Nature. 2024;630(8015):181–188. Doi:10.1038/s41586-024-07441-w.
3. Moor M, Banerjee O, Abad ZSH, et al. Foundation models for generalist medical artificial intelligence. Nature. 2023;616(7956):259–265. Doi:10.1038/s41586-023-05881
4. Bommasani R, Hudson DA, Adeli E, et al. On the opportunities and risks of foundation models. arXiv. 2021. Doi:10.48550/arXiv.2108.07258.
5. Dr. Ohmini Krishnamurthy Rajendran (Author), AI-BASED RADIOGENOMIC MODELS FOR PREDICTING IMMUNOTHERAPY RESPONSE IN SOLID TUMORS, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/321 , DOI: https://doi.org/10.46121/pspc.51.4.4
6. Dr. Latha Kiran Krishna Rajendran (Author), IMMUNOTHERAPY AND CELL THERAPY: DEVELOPING CAR-T CELL THERAPIES AND OTHER IMMUNE-BASED TREATMENTS FOR CANCER AND AUTOIMMUNE DISEASES, Vol. 51 No. 2 (2023): April-June 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/304 , DOI: https://doi.org/10.46121/pspc.51.2.7
7. Chakraborty, S. et al. (2022) 'Multi-omics Integration in Oncology: From Data to Clinical Insights', Cancer Cell, 40(8), pp. 805-823.
8. Dr. Ohmini Krishnamurthy Rajendran (Author), FEDERATED RADIOLOGY AI MODELS FOR MULTI-INSTITUTIONAL CANCER DIAGNOSIS WITHOUT DATA SHARING, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/323 , DOI: https://doi.org/10.46121/pspc.51.4.5

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv13i1206

Volume 13, Issue-12
December, 2023, P06
ISSN: 2319-9253

9. Dr. RajathaMaradiHemanth Kumar (Author), AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/388 , DOI: https://doi.org/10.46121/pspc.51.4.7
10. Joshi, A. et al. (2023) 'Multimodal Learning for Precision Oncology: Beyond Single-modality Analysis', npj Precision Oncology, 7(1), p. 28.
11. Huang, S.C. et al. (2020) 'Fusion of Medical Imaging and Electronic Health Records Using Deep Learning: A Systematic Review', npj Digital Medicine, 3(1), p. 136.
12. Dr. RajathaMaradiHemanth Kumar (Author), PAN-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/389, DOI: https://doi.org/10.46121/pspc.51.4.8
13. Lambin, P. et al. (2017) 'Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis', European Journal of Cancer, 48(4), pp. 441-446.
14. Zwanenburg, A. et al. (2023) 'The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping', Radiology, 308(2), e221422.
15. Chen, R.J. et al. (2023) 'Towards a General-Purpose Foundation Model for Computational Pathology', Nature Medicine, 29(4), pp. 850-862.
16. Kather, J.N. et al. (2022) 'Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations', Nature Cancer, 3(7), pp. 789-799.
17. Chaudhary, K. et al. (2021) 'Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer', Clinical Cancer Research, 27(5), pp. 1248-1259.
18. Cancer Genome Atlas Research Network (2013) 'The Cancer Genome Atlas Pan-Cancer Analysis Project', Nature Genetics, 45(10), pp. 1113-1120.
19. Huang, S.C. et al. (2021) 'Self-supervised Learning for Medical Image Classification: A Systematic Review', IEEE Transactions on Medical Imaging, 40(8), pp. 2021-2037.
20. Moor, M. et al. (2023) 'Foundation Models for Generalist Medical Artificial Intelligence', Nature, 616(7956), pp. 259-265.
21. Lambin, P. et al. (2017) 'Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis', European Journal of Cancer, 48(4), pp. 441-446.
22. Zwanenburg, A. et al. (2023) 'The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping', Radiology, 308(2), e221422.
23. Chen, R.J. et al. (2023) 'Towards a General-Purpose Foundation Model for Computational Pathology', Nature Medicine, 29(4), pp. 850-862.
24. Kather, J.N. et al. (2022) 'Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations', Nature Cancer, 3(7), pp. 789-799.
25. Chaudhary, K. et al. (2021) 'Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer', Clinical Cancer Research, 27(5), pp. 1248-1259.
26. Cancer Genome Atlas Research Network (2013) 'The Cancer Genome Atlas Pan-Cancer Analysis Project', Nature Genetics, 45(10), pp. 1113-1120.
27. Huang, S.C. et al. (2021) 'Self-supervised Learning for Medical Image Classification: A Systematic Review', IEEE Transactions on Medical Imaging, 40(8), pp. 2021-2037.
28. Moor, M. et al. (2023) 'Foundation Models for Generalist Medical Artificial Intelligence', Nature, 616(7956), pp. 259-265.
29. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46. Doi:10.1158/2159-8290.CD-21-1059.
30. Singhal K, Azizi S, Tu T, et al. Large language models encode clinical knowledge. Nature. 2023;620(7972):172–180. Doi:10.1038/s41586-023-06291-2.

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv13i1206